New Book by Psychiatrist and Mental Health Advocate, The Promise of Psychedelics, Launches Today
21 avr. 2022 10h00 HE
|
Ingenium Books
EDMONTON, Alberta, April 21, 2022 (GLOBE NEWSWIRE) -- Easy to read, yet backed by research, Dr. Peter Silverstone's new book, The Promise of Psychedelics: Science Based Hope for Better Mental...
Nexstim Receives an NBS 5+ System Order from a US Customer
06 avr. 2022 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 6 April 2022 at 9 AM (EEST) Nexstim Receives an NBS 5+ System Order from a US Customer Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces having received...
How Does a Fearful Experience Alter Our Past Memories?
05 avr. 2022 08h00 HE
|
Brain & Behavior Research Foundation
New York, April 05, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “How Does a Fearful Experience Alter Our Past Memories?” on Tuesday, April...
Rapid-acting Treatments for Pediatric Depression and Suicidality: Where are We Now?
03 mars 2022 08h00 HE
|
Brain & Behavior Research Foundation
New York, March 03, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, "Rapid-acting Treatments for Pediatric Depression and Suicidality: Where...
Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
22 févr. 2022 07h05 HE
|
Athira Pharma, Inc.
Oral presentation on neurotrophic and procognitive properties of the active metabolite of fosgonimeton in preclinical models First presentation of preclinical data from ATH-1020 candidate for...
United States $31.2 Bn Psychiatry Clinic Markets, 2021-2028 - Favourable Health Reimbursement & Increasing Demand for Mental Health Services
18 févr. 2022 06h43 HE
|
Research and Markets
Dublin, Feb. 18, 2022 (GLOBE NEWSWIRE) -- The "U.S. Psychiatry Clinic Market Size, Share & Trends Analysis Report by Age Group (Adult, Paediatric), and Segment Forecasts, 2021-2028" report has...
Neurocentria Obtains FDA Approval to Conduct Pivotal Phase IIb/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD
15 févr. 2022 09h00 HE
|
Neurocentria, Inc
WALNUT CREEK, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer's disease, Attention Deficit...
Investigating Neurobiology and New Treatments for Addiction, Depression and Anxiety
02 févr. 2022 11h05 HE
|
Brain & Behavior Research Foundation
New York, Feb. 02, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Investigating Neurobiology and New Treatments for Addiction, Depression...
CenExel Clinical Research Acquires California Neuroscience Research
10 janv. 2022 13h10 HE
|
CenExel Clinical Research
Salt Lake City, Utah, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical...
Prenatal Exposures and Experiences: Impact on Children’s Early Brain Development and Risk for Disease
10 janv. 2022 08h00 HE
|
Brain & Behavior Research Foundation
New York, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Prenatal Exposures and Experiences: Impact on Children’s Early Brain...